Longwood launches startup Solu with drug candidates from GSK and $31M to start
Longwood Fund’s Christoph Westphal, the co-founding investor behind the likes of Alnylam, TScan and Tome Biosciences, is out with another new biotech whose pipeline derives from GSK.
Boston-based Solu Therapeutics pulled back the curtains on Tuesday with $31 million in seed capital and drug candidates in-licensed from GSK. The biotech begins with a focus on hematological malignancies and anticipates entering the clinic within two years, co-founder and CEO David Donabedian said in a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.